ArticleJournal of pain research2025
A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy.
Nuo Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.